BioCentury | Nov 14, 2020
Product Development

ASH 2020 snapshot: efficacy data in hot emerging areas

...IgG1 mAb TTI-621 and the IgG4 mAb TTI-622...
...be able to deliver higher doses of TTI-622...
...mAbs, the company reported single-agent activity for TTI-622.Additionally...
BioCentury | Nov 11, 2020
Deals

Previewing CD47 efficacy data at SITC & ASH: Data Byte

...IgG1 mAb TTI-621 and the IgG4 mAb TTI-622...
...be able to deliver higher doses of TTI-622...
...the company reported single agent activity for TTI-622.Additionally...
BioCentury | Sep 10, 2020
Finance

Sept. 9 Quick Takes: OncoImmune, Inversago raise B rounds; plus Trillium-Pfizer, Biofourmis, LinkDoc, Singleron, Hrain, InxMed and MilleporeSigma

...of 2.3 million shares at $10.88, which will fund clinical testing of Trillium’s CD47 programs TTI-622...
BioCentury | Aug 10, 2019
Product Development

Eat this, don’t eat that: CD47 companies’ first hurdle

...NASDAQ:FTSV), Trillium Therapeutics Inc. (NASDAQ:TRIL; TSX:TRIL) and Innovent Biologics Inc. (HKEX:1801) are developing 5F9 , TTI-622...
...how far up in dose we need to go.” Trillium has developed a second compound, TTI-622...
...significant monotherapy activity. For us, it’s a combination play,” Uger said. He argues TTI-621 and TTI-622...
Items per page:
1 - 4 of 4